Stelara 90 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB26FWEYK
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,250
Award facts
- Contract value 100% obligated
- $16,249.95 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $16,249.95 to DMS Pharmaceutical Group Inc. for STELARA 90 mg/ml syringes, with an ultimate completion date of December 1, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order was issued under the company's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to support recurring pharmaceutical supply needs across Department of Defense healthcare facilities worldwide.
The PPV-G GEN V program establishes DMS Pharmaceutical Group as a regional prime vendor contractor authorized to supply a comprehensive range of pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables. This delivery order for Stelara, a biologic immunosuppressant used in treating conditions such as psoriasis and inflammatory bowel disease, reflects the company's role as a critical supplier within the federal military medical supply chain. The IDC, awarded November 13, 2025, carries a ceiling value of $499,999,999 with a completion date of December 31, 2036, structured with a 30-month base period and three 30-month option periods to ensure sustained pharmaceutical support for Department of Defense operations globally.
Quick answers
Who was awarded contract SPE2DB26FWEYK?
SPE2DB26FWEYK was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 6, 2025.
How much is contract SPE2DB26FWEYK worth?
The government has obligated $16,250 on SPE2DB26FWEYK.
Is contract SPE2DB26FWEYK an order under another contract?
Yes. SPE2DB26FWEYK is a delivery order under SPE2DB25D9320, an indefinite delivery contract.
Was contract SPE2DB26FWEYK competed?
The extent of competition for SPE2DB26FWEYK was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award